[Clinical studies on the use of gangliosides in acute cerebrovascular diseases].
20-40 Mg per day of gangliosides in association with the therapy already in use were given to patients suffering from acute cerebreal vascular lesions. The results reported in the present work refer to the time necessary for the return to normal functionality. It was observed that such parameter is practically half of that occuring in non-treated subjects. Therefore, the therapeutic usefulness of such glycolipids for the return to normal of the motor functionality and also of the coscience conditions of patients suffering from acute vascular CNS lesions is underlined.
D000208:Acute Disease; D000328:Adult; D000368:Aged; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005158:Facial Paralysis / Q000188:drug therapy; D005260:Female; D005732:Gangliosides / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged
D005732:Gangliosides
Osservazioni cliniche sull'uso dei gangliosidi nelle affezioni cerebro-vascolari acute